| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002042 | American Journal of Ophthalmology | 2015 | 9 Pages |
Abstract
The intraocular delivery of CNTF in the encapsulated cell implant appeared to be safe and well tolerated in eyes with macular telangiectasia type 2. Further evaluation in a randomized controlled clinical trial is warranted to test for efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Emily Y. Chew, Traci E. Clemons, Tunde Peto, Ferenc B. Sallo, Avner Ingerman, Weng Tao, Lawrence Singerman, Steven D. Schwartz, Neal S. Peachey, Alan C. Bird, MacTel-CNTF Research Group MacTel-CNTF Research Group,